Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy

Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years, trastuzumab, a monoclonal antibody, has been used to inhibit the HER2 activity. Though, the main resistance to trastuzumab has...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of cellular physiology Ročník 235; číslo 4; s. 3142 - 3156
Hlavní autori:	Derakhshani, Afshin, Rezaei, Zohreh, Safarpour, Hossein, Sabri, Morteza, Mir, Atefeh, Sanati, Mohammad Amin, Vahidian, Fatemeh, Gholamiyan Moghadam, Ali, Aghadoukht, Ali, Hajiasgharzadeh, Khalil, Baradaran, Behzad
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Wiley Subscription Services, Inc 01.04.2020
Predmet:	Antineoplastic Agents - pharmacology Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Combination therapy drug resistance Drug Resistance, Neoplasm - drug effects Epidermal growth factor ErbB-2 protein Growth factors HER2 positive Humans Immunotherapy Lapatinib - therapeutic use Monoclonal antibodies Receptor, ErbB-2 - drug effects Targeted cancer therapy Trastuzumab Trastuzumab - therapeutic use trastuzumab HER2 positive breast cancer drug resistance
ISSN:	0021-9541, 1097-4652, 1097-4652
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!